Welcome : Guest

Biogen, Inc. (USA) - Facts, Figures and Analytical Insights

Abstract

This report presents quick facts about Biogen, Inc., which is principally involved in Biopharmaceuticals Business. Illustrated with 26 tables, the report showcases the company's recent news stories and events, sales performance, key markets and market position as against its competitors operating in the industry.

Code: PCP-00559
Price: $1300
Company Type: Public
Pages: 30
Date: November 2016
Market Data Tables: 26

 NOTE : Select the checkbox below, and click Add to Cart button to add this report to your shopping cart.
Table 1: Biogen Idec, Inc.’s (Operations) Sales by Product Segment Worldwide (2014-2015) in Percentage for Multiple Sclerosis (Tecfidera, Interferon, Tysabri, and Fampyra), Hemophilia (Eloctate & Alprolix), and Fumaderm......3
Table 2: Biogen Idec, Inc.’s (Operations) Sales by Geographic Region Worldwide (2014-2015) in Percentage for U.S., Europe, Germany, Asia, and Others......4
Biopharmaceuticals......6
Table 3: Biopharmaceuticals Market by Segment Worldwide (2015) - Percentage Share Breakdown by Value for Norditropin, NovoSeven, Turoctocog Alpha, and Others......6
Multiple Sclerosis......7
Table 4: Multiple Sclerosis Disease Occurrence by Type Worldwide (2015) - Percentage Breakdown by Volume for Begin MS, Primary Progressive MS, Relapsing-Remiting MS, and Secondary Progressive MS......7
Table 5: Multiple Sclerosis Patient Care Expenditure by Category Worldwide (2015) - Percentage Breakdown by Value for Adaptations, Ambulatory Care, Disease Modifying Drugs, Early Retirement, Hospital Inpatient Care, Informal Care, Prescription and OTC Drugs, Services, Sick-leave and Redused Working Time, and Tests......8
Table 6: Relapsing-Remitting Multiple Sclerosis (RRMS) Market by Region Worldwide (2015) - Percentage Share Breakdown by Volume for European Union (EU), US, Rest of World (RoW)......9
Table 7: No. of Tcelna (Imilecleucel-T) Secondary Progressive Multiple Sclerosis Patients by Category in the US (2015) - Percentage Breakdown for Primary Progressive MS Patients, Relapsing-Remitting MS Patients, and Secondary-Progressive MS Patients......10
Hemophilia......11
Table 8: Hemophilia Market by Category Worldwide (2015) - Percentage Share Breakdown by Value Sales for Hemophilia A, Hemophilia B, Inhibitor, and Von Willebrand Disease......11
Table 9: Hemophilia Diagnosis and Treatments Rates by Category Worldwide (2015) - Percentage Market Share Breakdown by Value for Diagonised, Pristine Joints, Prophylactic, Treated, and Others......12
Table 10: Haemophilia by Severity Stage Worldwide (2015) - Percentage Market Share Breakdown by No. of Patients for Mild, Moderate and Severe......13
Table 11: Haemophilia Patient Population by Category Worldwide (2015) - Percentage Market Share Breakdown by Volume for Haemophilia A (Factor VIII Deficiency) and Haemophilia B (Factor IX Deficiency)......14
Table 12: Continuous Prophylaxis (Moderate) Treatment for Hemophilia A Patients by Category Worldwide (2015) - Percentage Market Share Breakdown by Value for 0-12, 13-21 and 22+......15
Table 13: Continuous Prophylaxis Treatment (Severe) for Hemophilia A Patients by Age Group Worldwide (2015) - Percentage Market Share Breakdown by Value for 0-12, 13-21 and 22+......16
Table 14: On-Demand (Moderate Patient) Treatment for Hemophilia A Patients by Category Worldwide (2015) - Percentage Market Share Breakdown by Value for 0-12, 13-21 and 22+......17
Table 15: On-Demand (Severe Patient) Treatment for Hemophilia A Patients by Category Worldwide (2015) - Percentage Market Share Breakdown by Value for 0-12, 13-21 and 22+......18
Table 16: Haemophilia B - Recombinant (Benefix) Sales by Region Worldwide (2015) - Percentage Market Share Breakdown by Value for Emerging Markets, Europe, US, and Others......19
Table 17: Immune Tolerance Therapy (Patient) Treatment for Hemophilia A Patients by Category Worldwide (2015) - Percentage Market Share Breakdown by Value for 0-12, 13-21 and 22+......20
Table 18: Intermittent Prophylaxis (Moderate Patient Equivalent) Treatment for Hemophilia A Patients by Category Worldwide (2015) - Percentage Market Share Breakdown by Value for 0-12, 13-21 and 22+......21
Table 19: Intermittent Prophylaxis (Severe Patient Equivalent) Treatment for Hemophilia A Patients by Category Worldwide (2015) - Percentage Market Share Breakdown by Value for 0-12, 13-21 and 22+......22
Table 20: U.S. Hemophilia Market Patients Treated/Year (2014)......23
Biopharmaceuticals......24
Table 21: Market Shares of Leading Biopharmaceutical Companies Worldwide (2014) - Percentage Breakdown by Volume (Installed Capacity) for Amgen Inc., Biogen Idec, Inc., Bristol-Myers Squibb Company, C.H. Boehringer Sohn AG & Co. KG, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Johnson & Johnson Ltd., Lonza Group Ltd., Pfizer, Inc., Sanofi S.A., and Others......24
Table 22: Market Shares of Leading Biopharmaceutical Companies in the US (2015) - Percentage Market Share Breakdown by Value for Actelion Pharmaceuticals Ltd., Alexion Pharmaceuticals, Inc., Celgene Corporation, Gilead Sciences, Inc., Incyte, Corporation, Isis Pharmaceuticals, Inc., Vertex Pharmaceuticals, Inc., and Others......25
Multiple Sclerosis......26
Table 23: Market Shares of Leading Multiple Sclerosis Therapeutic Providers by Value Sales Worldwide (2014) - Percentage Breakdown for Biogen Idec, Novartis AG, Sanofi S.A., and Others......26
Table 24: Market Shares of Leading Drug Brands for Relapsing-Remitting Multiple Sclerosis (RRMS) Worldwide (2015) - Percentage Breakdown by No. of Patients for Avonex, Betaseron, Copaxone, Gilenya, Laquinimod, Rebif, Tysabri, and Others......27
Table 25: Market Shares of Leading Drug Brands for Relapsing-Remitting Multiple Sclerosis (RRMS) Worldwide (2015) - Percentage Breakdown by Value for Avonex, Betaseron, Copaxone, Gilenya, Laquinimod, Rebif, Tysabri, and Others......28
Table 26: Biogen Idec, Inc.’s Sales by Geographic Region Worldwide (2011-2013) in US$ Million for United States, Rest of World, Unconsolidated Joint Business Revenues, and Other Revenues......29